Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $9.6852W HIGH $25.77
Volume
243.42 K
Value Traded
13.18 M
Short % Float
32.72%
Days to Cover
18.0
-1.83%Week
-10.63%1 Month
-53.61%3 Month
-45.75%6 Month
-14.5%5 Year
-14.5%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
886.83 M
EPS (TTM)
-1.89
P/E Ratio
-
Ent. Value
273.83 M
Total Shares
85.31 M
Float Shares
60.17 M
Insiders
29.47%
Institutions
89.39%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
GLUE Catalyst Timeline
Dated clinical, regulatory and corporate events for Monte Rosa Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Monte Rosa Therapeutics, Inc.
209Total events
16Upcoming
36Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Topline ReadoutMRT-8102Clinical Data
Monte Rosa announces positive GFORCE-1 Phase 1 results for MRT-8102 in obese subjects with elevated CVD risk
Elevated cardiovascular disease risk / ASCVDsource ↗
▲Biomarker DataMRT-8102Clinical Data
MRT-8102 achieved robust and sustained NEK7 degradation and reductions in ASCVD biomarkers in GFORCE-1
Elevated cardiovascular disease (CVD) risk / ASCVDsource ↗
▲Safety Data UpdateMRT-8102Clinical Data
MRT-8102 was safe and well tolerated over four weeks of dosing and four weeks of follow-up in GFORCE-1
Elevated cardiovascular disease (CVD) risk / ASCVDsource ↗
▲Primary Endpoint MetMRT-8102Clinical Data
MRT-8102 achieved robust NEK7 degradation and favorable safety in GFORCE-1
Elevated cardiovascular disease risk / ASCVDsource ↗
▲Trial InitiationMRT-6160Trial
Novartis initiates Phase 2 clinical study of MRT-6160 (DDY391) in Sjögren's disease
Sjögren's diseasesource ↗
▲Milestone PaymentMRT-6160Corporate
Monte Rosa to receive $50 million milestone payment from Novartis based on first patient visit of Phase 2 study
Sjögren's diseasesource ↗
▲First Patient DosedMRT-6160Trial
First patient visit in Phase 2 study of MRT-6160 (DDY391) in Sjögren's disease
Sjögren's diseasesource ↗
▲First Patient DosedMRT-2359Trial
First patient dosed in Phase 2 MODeFIRe-1 study of MRT-2359 in combination with apalutamide
metastatic castration-resistant prostate cancer (mCRPC) with AR mutationssource ↗
▲Enrollment CompleteMRT-2359Trial
Enrollment completed in initial Phase 1/2 study expansion arm in advanced CRPC patients
advanced CRPCsource ↗
▲Trial InitiationMRT-6160Trial
Phase 2 study of MRT-6160 activated by Novartis
Sjögren's diseasesource ↗
▲Trial InitiationMRT-2359Trial
MODeFIRe-1 Phase 2 study activated
metastatic castration-resistant prostate cancersource ↗
▲Enrollment CompleteMRT-2359Trial
Enrollment completed in initial Phase 1/2 expansion arm
advanced CRPCsource ↗
◆First Patient DosedMRT-2359Trial
First patient dosing in MODeFIRe-1 expected
metastatic castration-resistant prostate cancersource ↗
◆Topline ReadoutMRT-8102Clinical Data
Readout of GFORCE-1 study anticipated
elevated cardiovascular disease risksource ↗
◆Trial InitiationMRT-8102Trial
Initiation of GFORCE-2 Phase 2b study expected
elevated atherosclerotic risk and cardiometabolic syndromesource ↗
▲Enrollment CompleteMRT-8102Trial
Completed enrollment and dosing for GFORCE-1 study
elevated cardiovascular disease risksource ↗
◆Oral PresentationMRT-55811Presentation
Oral presentation of preclinical data for MRT-55811 at AACR 2026
CCNE1-amplified solid tumorssource ↗
▲Safety Data UpdateMRT-8102Clinical Data
Unblinded safety data from MRT-8102 SAD/MAD cohorts support favorable safety profile
elevated CVD risksource ↗
●Management ChangeCorporate
Promoted Magnus Walter to Chief Technology Officer and Andrew Funderburk to Chief Investor Relations and Strategy Officer
●Oral PresentationMRT-2359Presentation
Interim data presented at ASCO GU in February
advanced CRPCsource ↗
◆Poster PresentationMRT-2359Presentation
Poster presentation at ASCO GU 2026
metastatic castration-resistant prostate cancersource ↗
▲Oral PresentationMRT-2359Presentation
Presentation of interim Phase 1/2 data of MRT-2359 at ASCO GU
mCRPCsource ↗
▲Interim AnalysisMRT-2359Trial
Positive interim data from Phase 1/2 study of MRT-2359 in combination with enzalutamide showing 100% PSA response rate in mCRPC patients with AR mutations
metastatic castration-resistant prostate cancer (mCRPC) with AR mutationssource ↗
▼Equity OfferingCorporate
Pricing of $300 million underwritten public offering of common stock and pre-funded warrants
▲Topline ReadoutMRT-8102Clinical Data
Positive interim Phase 1 data of MRT-8102 showing 85% CRP reduction
elevated cardiovascular disease risksource ↗
◆IND SubmissionMRT-55811IND
IND submission for cyclin E1-directed MGD MRT-55811
CCNE1-amplified solid tumorssource ↗
▲Topline ReadoutMRT-8102Clinical Data
Interim data from GFORCE-1 trial of MRT-8102 showed profound CRP reductions
elevated CVD risksource ↗
▲Interim AnalysisMRT-8102Trial
Positive interim Phase 1 data of MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects
elevated CVD risksource ↗
◆IND SubmissionIND
IND submission for second-generation NEK7-directed MGD
inflammatory diseasessource ↗
▲Poster PresentationMRT-55811Presentation
Preclinical data on cyclin E1-directed MGD presented at AACR 2026
CCNE1-amplified solid tumorssource ↗
▼Equity OfferingCorporate
Closed upsized underwritten public offering of common stock and pre-funded warrants for gross proceeds of approximately $345 million
◆Oral PresentationMRT-2359Presentation
Management to host webcast highlighting interim clinical results from Phase 1/2 study of MRT-2359 in mCRPC
metastatic castration-resistant prostate cancer (mCRPC)source ↗
▲Interim AnalysisMRT-2359Trial
Positive interim data from Phase 1/2 study of MRT-2359 + enzalutamide in mCRPC
metastatic castration-resistant prostate cancersource ↗
▲First Patient DosedMRT-8102Trial
Initiated dosing in Part 3 of Phase 1 study of MRT-8102
inflammatory diseases (NLRP3 inflammasome)source ↗
◆Full ResultsMRT-2359Clinical Data
Additional results from MRT-2359 in mCRPC expected by year-end
Metastatic castration-resistant prostate cancer (mCRPC)source ↗
▲Milestone PaymentCorporate
Achieved preclinical milestone under Roche collaboration, triggering $7 million milestone payment
●Poster PresentationMRT-8102Presentation
Poster presentation at AHA Scientific Sessions 2025 on preclinical data for MRT-8102
cardiovascular and cardiometabolic diseasessource ↗
◆Oral PresentationPresentation
Participation in upcoming investor conferences with fireside chats
◆Poster PresentationMRT-6160Presentation
Poster presentation at ACR Convergence 2025 on preclinical data for MRT-6160
autoimmune and inflammatory diseases (Sjögren’s disease, systemic lupus erythematosus, rheumatoid arthritis)source ↗
▼Equity OfferingCorporate
At-the-market offering of 2,955,082 shares for $25.0 million gross proceeds
▲Partnership / LicenseCorporate
Collaboration with Novartis for degraders to treat immune-mediated diseases
immune-mediated diseasessource ↗
▲Partnership / LicenseCorporate
Second agreement with Novartis to develop novel degraders for immune-mediated diseases; upfront payment of $120 million
Past FDA Catalysts and PDUFA Decisions
How GLUE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-01 | MRT-8102 (NEK7-directed MGD) | Phase 1 data presentation | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 34%
Micro Cap(rank 224 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MRT-2359 Small moleculeNCT07745361 | Castration-Resistant Prostate Cancer (CRPC) | Phase 2 | RECRUITING | 25 | Apr 1, 2028 | ||||||
| MRT-2359 Small moleculeNCT05546268 | NSCLC | Phase 1 | ACTIVE NOT_RECRUITING | 174 | Nov 1, 2027 | ||||||
| MRT-8102 Small moleculeNCT07119125 | Undisclosed | Phase 1 | ACTIVE NOT_RECRUITING | 100 | Jul 1, 2026 | ||||||
| MRT-6160 Small moleculeCompletedNCT06597799 | Undisclosed | Phase 1 | COMPLETED | 108 | Apr 10, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every GLUE program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| MRT-8102 | atherosclerotic cardiovascular disease (ASCVD) | Phase 1 | 2026-10-01 | Robust and sustained NEK7 degradation observed across 5 mg, 20 mg, and 40 mg once-daily dose levels; HMGB1, calprotectin, S100A12, and SAA reduced to levels comparable to normal physiological levels; No serious adverse events reported; Treatment-emergent adverse event rates comparable to placeboRead More | Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD RiskRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Bowen MatthewOfficer (Principal Accounting Officer) | Sell | -13 25,891 held | $10.56 | 10/05/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in GLUE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| NEA Management Company, LLC | 11.7 % (62.5 %) | 186.15 M | 7.69 M |
GLUE Institutional Ownership Trends
GLUE Short Interest
Shares sold short, counted twice a month.
32.72%
Short % of Float
of tradable shares sold short
19.7M
Shares Sold Short
+2.2% vs prior count
18.0 Very high
Days to Cover
trading days of normal volume to buy every short share back
1.1M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How GLUE ranks across every disease it competes in
Competitive Position is a premium feature
See how GLUE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialGLUE News
GLUEMonte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Monte Rosa Therapeutics has announced the grant of inducement equity awards to five new non-executive employees as part of their hiring process. The awards include stock options and restricted stock units, which will vest over time, contingent on continued employment. This initiative is in accordance with Nasdaq Listing Rule 5635(c)(4) and aims to attract skilled professionals to the company.
Read more →GLUE▼ -5.6%on this news· ran to -17% by day 3shared move
Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk
Monte Rosa Therapeutics announced positive results from the GFORCE-1 Phase 1 study of MRT-8102, a NEK7-directed molecular glue degrader. The study demonstrated significant normalization of pathogenic drivers associated with atherosclerotic cardiovascular disease (ASCVD) in obese subjects at elevated cardiovascular risk. MRT-8102 was well tolerated, with no serious adverse events reported. Plans for Phase 2 trials in coronary artery disease, gout, and hidradenitis suppurativa are underway.
Read more →GLUE▼ -5.6%on this news· ran to -17% by day 3shared move
Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk
Monte Rosa Therapeutics will present results from the GFORCE-1 Phase 1 study of MRT-8102, a molecular glue degrader targeting cardiovascular disease. The presentation will cover safety and activity data after four weeks of treatment. This study aims to address multiple pathogenic drivers of atherosclerotic cardiovascular disease, highlighting the innovative approach of MRT-8102.
Read more →GLUEMonte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
Monte Rosa Therapeutics has announced the initiation of a Phase 2 clinical study for MRT-6160 (DDY391) in patients with Sjögren's disease, in collaboration with Novartis. This milestone triggers a $50 million payment to Monte Rosa and marks the beginning of further studies aimed at evaluating the drug's potential across various immune-mediated diseases. MRT-6160 has shown promising results in previous trials, indicating its efficacy and safety.
Read more →GLUEMonte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics, a clinical-stage biotechnology company, announced its participation in two upcoming investor conferences: the Wells Fargo 21st Annual Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. CEO Markus Warmuth will engage in a fireside chat at the Wells Fargo event. The company focuses on developing novel molecular glue degrader medicines for serious diseases.
Read more →GLUEMonte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
Monte Rosa Therapeutics has initiated dosing in the MODeFIRe-1 Phase 2 study, evaluating MRT-2359 combined with apalutamide for patients with AR mutation-positive metastatic castration-resistant prostate cancer. This study follows positive results from earlier trials, highlighting MRT-2359's potential in a patient group with few therapeutic options. The trial aims to assess various efficacy and safety endpoints.
Read more →GLUEMonte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
Monte Rosa Therapeutics reported its second quarter 2026 financial results, highlighting significant progress in its clinical programs. The company has completed enrollment for the GFORCE-1 study of MRT-8102 and anticipates multiple Phase 2 studies to initiate in the coming months. Despite a net loss increase and decreased collaboration revenue, the company maintains a strong cash position to support ongoing operations.
Read more →GLUEMonte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 2, 2026
Monte Rosa Therapeutics has granted inducement equity awards to four new non-executive employees as part of their employment agreement. The awards include stock options and restricted stock units, which will vest over time. This initiative is part of the company's strategy to enhance its workforce while adhering to Nasdaq Listing Rule 5635(c)(4). Monte Rosa is focused on developing novel molecular glue degrader medicines for serious diseases.
Read more →GLUEMonte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Monte Rosa Therapeutics reported financial results for Q1 2026, highlighting strong progress in its clinical programs. The interim data from the GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated substantial reductions in CRP levels among subjects at high cardiovascular risk. The company anticipates the initiation of multiple Phase 2 studies for MRT-8102 and MRT-2359 in various indications, including atherosclerotic risk and metastatic castration-resistant prostate cancer. Monte Rosa maintains a robust financial position with $671 million in cash and equivalents.
Read more →GLUE▲ +5.4%on this newsshared move
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 5, 2026
Monte Rosa Therapeutics announced the grant of inducement equity awards to four new non-executive employees as part of their employment package. The awards include non-qualified stock options and restricted stock units, which will vest over time. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to attracting skilled professionals.
Read more →GLUEMonte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
Monte Rosa Therapeutics presented preclinical data on MRT-55811, a cyclin E1-directed molecular glue degrader, at the AACR Annual Meeting 2026. The data showed that MRT-55811 induced significant tumor regressions in CCNE1-amplified cancer models, exhibiting high selectivity and reduced off-target effects compared to existing treatments. The company plans to submit an IND for MRT-55811 later this year.
Read more →GLUEMonte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Monte Rosa Therapeutics reported positive interim data for MRT-8102, showing significant reductions in CRP levels in patients at elevated cardiovascular risk. The company plans to initiate multiple Phase 2 studies for MRT-8102 and MRT-2359 in the coming years. Financially, Monte Rosa strengthened its position with a $345 million follow-on financing, supporting its development pipeline through 2029.
Read more →GLUEMonte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Read more →GLUEMonte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
Monte Rosa Therapeutics presented updated clinical data for MRT-2359 at the ASCO GU Symposium, showing a 100% PSA response rate in mCRPC patients with AR mutations. The combination with enzalutamide demonstrated a 67% overall disease control rate. The treatment was well-tolerated, prompting plans for a Phase 2 study to further evaluate MRT-2359's efficacy.
Read more →GLUE▲ +8.7%on this news
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
Monte Rosa Therapeutics has announced the pricing of an underwritten public offering, aiming to raise $300 million through the sale of 11,125,000 shares at $24.00 each. The offering includes pre-funded warrants for certain investors, representing further stock options. The proceeds are intended to support the company's development of novel molecular glue degrader (MGD)-based therapies. The offering is set to close on or around January 12, 2026, pending closing conditions.
Read more →GLUE▲ +45.4%on this news· ran to +58% by day 1shared move
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects
Monte Rosa Therapeutics reported positive interim data from its Phase 1 study of MRT-8102, which showed significant reductions in C-reactive protein (CRP) levels in subjects at elevated cardiovascular disease risk. After four weeks of treatment, 94% of participants achieved CRP levels below the threshold associated with reduced CVD risk. The study also indicated a favorable safety profile and plans for further development in Phase 2 studies targeting atherosclerotic cardiovascular disease.
Read more →About Monte Rosa Therapeutics, Inc.
Headquarters321 HARRISON AVENUE, BOSTON, MA, 02118
BIOPHARMAWATCH ELITE PLUS
Trade the next GLUE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime